FORMULATION AND EVALUATION OF GLICLAZIDE CONTROLLED RELEASE TABLETS USING SODIUM ALGINATE, HPMC H4H IN DIFFERENT PROPORTIONS

Gliclazide is a second-generation sulfonylurea widely used in the management of type 2 diabetes mellitus. It acts by stimulating insulin secretion from pancreatic β-cells through the closure of ATP-sensitive potassium channels, thereby improving glycemic control. In addition to its hypoglycemic effect, gliclazide exhibits beneficial antioxidant and hemovascular properties, which reduce oxidative stress and improve microcirculation. Compared to other sulfonylureas, gliclazide is associated with a lower risk of hypoglycemia and favorable cardiovascular safety. It shows good oral bioavailability and is commonly formulated as immediate-release and modified-release tablets to enhance patient compliance. Due to its efficacy, safety profile, and cost-effectiveness, gliclazide remains an important therapeutic option in the long-term treatment of type 2 diabetes mellitus. Gliclazide is commonly formulated as a modified-release dosage form to provide sustained glycemic control in patients with type 2 diabetes mellitus. Controlled-release formulations maintain steady plasma drug concentrations, thereby reducing fluctuations in blood glucose levels and minimizing the risk of hypoglycemia. The use of hydrophilic polymers such as HPMC and ethyl cellulose enhances drug release modulation and improves patient compliance by reducing dosing frequency. Controlled-release gliclazide tablets demonstrate improved therapeutic outcomes, better tolerability, and enhanced quality of life in diabetic patients. These formulations represent an effective approach for long-term diabetes management.